

Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030

<https://marketpublishers.com/r/C9F5FA752FE1EN.html>

Date: March 2025

Pages: 311

Price: US\$ 4,950.00 (Single User License)

ID: C9F5FA752FE1EN

Abstracts

The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.

This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.

“The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period.”

Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence

of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.

“The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market.”

Based on therapeutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.

“Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region.”

The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for central lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%

By Designation: C-level–25%, Director-level–30% and Others–45%

By Region: North America–40%, Europe–25%, Asia Pacific–20%, Latin America-10%, and Middle east and Africa – 5%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 =

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.3 STUDY SCOPE

1.3.1 MARKETS COVERED AND REGIONAL SCOPE

1.3.2 INCLUSIONS AND EXCLUSIONS

1.3.3 YEARS CONSIDERED

1.4 CURRENCY CONSIDERED

1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

2.1.2.1 Primary sources

2.1.2.2 Key industry insights

2.1.2.3 Key data from primary sources

2.1.2.4 Breakdown of primary interviews

2.2 MARKET SIZE ESTIMATION

2.2.1 BOTTOM-UP APPROACH

2.2.1.1 Approach 1: Company revenue estimation approach

2.2.1.2 Approach 2: Presentations of companies and primary interviews

2.2.1.3 Approach 3: Primary interviews

2.2.1.4 Growth forecast

2.2.1.5 CAGR projections

2.2.2 TOP-DOWN APPROACH

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

2.4 RESEARCH ASSUMPTIONS

2.4.1 STUDY-RELATED ASSUMPTIONS

2.4.2 PARAMETRIC ASSUMPTIONS

2.5 RESEARCH LIMITATIONS

2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW
- 4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER AND COUNTRY
- 4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY
- 4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 DRIVERS
 - 5.2.1.1 Increasing number of clinical trials
 - 5.2.1.2 Rising investments in research & development
 - 5.2.1.3 Growing prevalence of rare diseases
 - 5.2.1.4 Favorable government initiatives
 - 5.2.2 RESTRAINTS
 - 5.2.2.1 High costs associated with clinical trials
 - 5.2.2.2 Shortage of skilled professionals
 - 5.2.3 OPPORTUNITIES
 - 5.2.3.1 Emerging markets worldwide
 - 5.2.3.2 Decentralized and virtual clinical trials
 - 5.2.4 CHALLENGES
 - 5.2.4.1 Regulatory complexities
 - 5.2.4.2 Limited patient diversity
 - 5.2.4.3 Cybersecurity and intellectual property concerns
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 VALUE CHAIN ANALYSIS
 - 5.4.1 RESOURCE ACQUISITION AND PREPARATION
 - 5.4.2 CLINICAL TRIAL EXECUTION
 - 5.4.3 DATA REPORTING AND RESULT SUBMISSION
 - 5.4.4 PROMOTION AND REGULATORY FILING
- 5.5 ECOSYSTEM ANALYSIS

5.6 INVESTMENT AND FUNDING SCENARIO

5.7 TECHNOLOGY ANALYSIS

5.7.1 KEY TECHNOLOGIES

5.7.1.1 Enzyme-linked immunosorbent assay

5.7.2 ADJACENT TECHNOLOGIES

5.7.2.1 Next-generation sequencing

5.8 KEY CONFERENCES AND EVENTS, 2025–2026

5.9 CASE STUDY ANALYSIS

5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)

5.10 REGULATORY LANDSCAPE

5.10.1 REGULATORY FRAMEWORK

5.10.1.1 North America

5.10.1.2 Europe

5.10.1.3 Asia Pacific

5.10.1.4 Rest of the World

5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.11 PORTER'S FIVE FORCES ANALYSIS

5.11.1 THREAT OF NEW ENTRANTS

5.11.2 THREAT OF SUBSTITUTES

5.11.3 BARGAINING POWER OF SUPPLIERS

5.11.4 BARGAINING POWER OF BUYERS

5.11.5 INTENSITY OF COMPETITIVE RIVALRY

5.12 KEY STAKEHOLDERS AND BUYING CRITERIA

5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.12.2 BUYING CRITERIA

5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET

5.13.1 INTRODUCTION

5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES

5.13.3 AI USE CASES

5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM

6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE

6.1 INTRODUCTION

6.2 PHASE I

6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH

6.3 PHASE II

6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET

6.4 PHASE III

6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET

6.5 PHASE IV

6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH

7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,

BY SERVICE TYPE

7.1 INTRODUCTION

7.2 SAFETY TESTING

7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH

7.3 IMMUNOLOGY

7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH

7.4 GENETIC TESTING

7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET

7.5 COAGULATION TESTING

7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH

7.6 PATHOLOGY TESTING

7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH

7.7 BIOMARKERS

7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH

7.8 COMPANION DIAGNOSTICS

7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET

7.9 OTHER TESTS

8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,

BY THERAPEUTIC AREA**8.1 INTRODUCTION****8.2 ONCOLOGY****8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH****8.3 INFECTIOUS DISEASES****8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH****8.4 NEUROLOGY****8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH****8.5 CARDIOLOGY****8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET****8.6 OTHER THERAPEUTIC AREAS****9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,****BY MODALITY****9.1 INTRODUCTION****9.2 SMALL MOLECULES****9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH****9.3 BIOLOGICS****9.3.1 MONOCLONAL ANTIBODIES****9.3.1.1 Growing advancements in antibody engineering to drive market****9.3.2 VACCINES****9.3.2.1 Increasing investments in vaccine development to favor growth****9.3.3 OTHER THERAPEUTIC PRODUCTS****9.4 CELL & GENE THERAPY****9.4.1 OUTSOURCING TREND TO FAVOR GROWTH****9.5 MEDICAL DEVICES & IVD DEVICES****9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET****10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,****BY END USER****10.1 INTRODUCTION****10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES**

- 10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
- 10.3 CLINICAL RESEARCH ORGANIZATIONS
 - 10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
- 10.4 MEDICAL DEVICE COMPANIES
 - 10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
- 10.5 OTHER END USERS

11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,

BY REGION

- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
 - 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 - 11.2.2 US
 - 11.2.2.1 Increasing clinical trials to support growth
 - 11.2.3 CANADA
 - 11.2.3.1 Rising incidence of chronic diseases to advance growth
- 11.3 EUROPE
 - 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
 - 11.3.2 GERMANY
 - 11.3.2.1 Increasing healthcare expenditure to intensify growth
 - 11.3.3 FRANCE
 - 11.3.3.1 Growing investments in life sciences sector to boost market
 - 11.3.4 UK
 - 11.3.4.1 High number of oncology clinical trials to facilitate growth
 - 11.3.5 ITALY
 - 11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth
 - 11.3.6 SPAIN
 - 11.3.6.1 Emerging biotech companies to bolster growth
 - 11.3.7 REST OF EUROPE
- 11.4 ASIA PACIFIC
 - 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 - 11.4.2 JAPAN
 - 11.4.2.1 Growing demand for drug development to propel market
 - 11.4.3 CHINA
 - 11.4.3.1 Booming pharmaceutical industry to drive market
 - 11.4.4 INDIA

11.4.4.1 Increasing regulatory reforms to foster growth

11.4.5 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH

11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

11.6 MIDDLE EAST & AFRICA

11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET

11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL
LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET

12.3 REVENUE ANALYSIS, 2020?2024

12.4 MARKET SHARE ANALYSIS, 2024

12.5 COMPANY VALUATION AND FINANCIAL METRICS

12.6 BRAND/PRODUCT COMPARISON

12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

12.7.1 STARS

12.7.2 EMERGING LEADERS

12.7.3 PERVASIVE PLAYERS

12.7.4 PARTICIPANTS

12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

12.7.5.1 Company footprint

12.7.5.2 Region footprint

12.7.5.3 Product type footprint

12.7.5.4 Therapeutic area footprint

12.7.5.5 Phase footprint

12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

12.8.1 PROGRESSIVE COMPANIES

12.8.2 RESPONSIVE COMPANIES

12.8.3 DYNAMIC COMPANIES

12.8.4 STARTING BLOCKS

12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

12.8.5.1 Detailed list of key startups/SMEs

12.8.5.2 Competitive benchmarking of key startups/SMEs

12.9 COMPETITIVE SCENARIO

- 12.9.1 PRODUCT LAUNCHES
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 THERMO FISHER SCIENTIFIC INC.

- 13.1.1.1 Business overview
- 13.1.1.2 Products/Services offered
- 13.1.1.3 Recent developments
 - 13.1.1.3.1 Product launches
 - 13.1.1.3.2 Deals
 - 13.1.1.3.3 Expansions
- 13.1.1.4 MnM view
 - 13.1.1.4.1 Key strengths
 - 13.1.1.4.2 Strategic choices
 - 13.1.1.4.3 Weaknesses and competitive threats

13.1.2 IQVIA

- 13.1.2.1 Business overview
- 13.1.2.2 Products/Services offered
- 13.1.2.3 Recent developments
 - 13.1.2.3.1 Product launches
 - 13.1.2.3.2 Deals
- 13.1.2.4 MnM view
 - 13.1.2.4.1 Right to win
 - 13.1.2.4.2 Strategic choices
 - 13.1.2.4.3 Weaknesses and competitive threats

13.1.3 ICON PLC

- 13.1.3.1 Business overview
- 13.1.3.2 Products/Services offered
- 13.1.3.3 Recent developments
 - 13.1.3.3.1 Product launches
 - 13.1.3.3.2 Deals
- 13.1.3.4 MnM view
 - 13.1.3.4.1 Right to win
 - 13.1.3.4.2 Strategic choices
 - 13.1.3.4.3 Weaknesses and competitive threats

13.1.4 CHARLES RIVER LABORATORIES

- 13.1.4.1 Business overview
- 13.1.4.2 Products/Services offered
- 13.1.4.3 Recent developments
 - 13.1.4.3.1 Deals
 - 13.1.4.3.2 Expansions
- 13.1.4.4 MnM view
 - 13.1.4.4.1 Right to win
 - 13.1.4.4.2 Strategic choices
 - 13.1.4.4.3 Weaknesses and competitive threats

13.1.5 LABCORP

- 13.1.5.1 Business overview
- 13.1.5.2 Products/Services offered
- 13.1.5.3 Recent developments
 - 13.1.5.3.1 Product launches
 - 13.1.5.3.2 Deals
 - 13.1.5.3.3 Expansions
 - 13.1.5.3.4 Other developments
- 13.1.5.4 MnM view
 - 13.1.5.4.1 Key strengths
 - 13.1.5.4.2 Strategic choices
 - 13.1.5.4.3 Weaknesses and competitive threats

13.1.6 QUEST DIAGNOSTICS

- 13.1.6.1 Business overview
- 13.1.6.2 Products/Services offered
- 13.1.6.3 Recent developments
 - 13.1.6.3.1 Deals

13.1.7 MEDPACE

- 13.1.7.1 Business overview
- 13.1.7.2 Products/Services offered
- 13.1.7.3 Recent developments
 - 13.1.7.3.1 Expansions

13.1.8 FRONTAGE LABS

- 13.1.8.1 Business overview
- 13.1.8.2 Products/Services offered

13.1.9 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA

- 13.1.9.1 Business overview
- 13.1.9.2 Products/Services offered
- 13.1.9.3 Recent developments

13.1.9.3.1 Deals

13.1.10 EUROFINS SCIENTIFIC

13.1.10.1 Business overview

13.1.10.2 Products/Services offered

13.1.10.3 Recent developments

13.1.10.3.1 Deals

13.1.11 REPROCELL INC.

13.1.11.1 Business overview

13.1.11.2 Products/Services offered

13.1.11.3 Recent developments

13.1.11.3.1 Deals

13.1.12 ACM GLOBAL LABORATORIES

13.1.12.1 Business overview

13.1.12.2 Products/Services offered

13.1.12.3 Recent developments

13.1.12.3.1 Deals

13.2 OTHER PLAYERS

13.2.1 WORLDWIDE CLINICAL TRIALS

13.2.2 VERSITI

13.2.3 CTI CLINICAL TRIAL & CONSULTING

13.2.4 CLARITY LABORATORIES, INC

13.2.5 NOVOTECH

13.2.6 ARUP LABORATORIES

13.2.7 PRECISION MEDICINE GROUP

13.2.8 BIOAGILYTIX LABS

13.2.9 CERBA HEALTHCARE

13.2.10 ALMAC GROUP

13.2.11 MLM MEDICAL LABS

13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP

13.2.13 UNILABS

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

I would like to order

Product name: Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/C9F5FA752FE1EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9F5FA752FE1EN.html>